Ramucirumab Beneficial in Advanced Gastric/GEJ Cancers Regardless of Age
Regardless of age, patients with advanced gastric or gastroesophageal juncture (GEJ) cancer saw a survival benefit when treated with the monoclonal antibody... Read More
For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org
Together, we will defeat stomach cancer.
Together, we will defeat stomach cancer.
MORE INFODONATE